Quick Answer
Corbus Pharmaceuticals Holdings, Inc. reported Net Income Loss of -$78.54 million for the year ending 2025.
- Corbus Pharmaceuticals Holdings, Inc. showed a decrease of -95.3% in Net Income Loss from 2024 to 2025.
- This data is from Corbus Pharmaceuticals Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Corbus Pharmaceuticals Holdings, Inc.'s Net Income Loss has declined by 12,938.4%.
- Historical annual values: Fiscal year 2025: -$78.54 million | Fiscal year 2024: -$40.21 million | Fiscal year 2023: -$44.60 million | Fiscal year 2022: -$42.35 million | Fiscal year 2021: -$45.64 million | Fiscal year 2020: -$111.27 million | Fiscal year 2019: -$71.45 million | Fiscal year 2018: -$55.67 million | Fiscal year 2017: -$32.42 million | Fiscal year 2016: -$20.00 million | Fiscal year 2015: -$8.85 million | Fiscal year 2014: -$2.54 million | Fiscal year 2013: -$602.4 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: